@article{01GVMXJ9KQCT30H93HFE1W58N0,
  abstract     = {{Expression of inhibitory designer receptors exclusively activated by designer drugs (DREADDs) on excitatory hippocampal neurons in the hippocampus represents a potential new therapeutic strategy for drug-resistant epilepsy. To overcome the limitations of the commonly used DREADD agonist clozapine, we investigated the efficacy of the novel DREADD ligand JHU37160 in chemogenetic seizure suppression in the intrahippocampal kainic acid (IHKA) mouse model for temporal lobe epilepsy (TLE). In addition, seizure-suppressing effects of chemogenetics were compared to the commonly used anti-epileptic drug (AED), levetiracetam (LEV). Therefore, an adeno-associated viral vector was injected in the sclerotic hippocampus of IHKA mice to induce expression of a tagged inhibitory DREADD hM4Di or only a tag (control) specifically in excitatory neurons using the CamKII alpha promoter. Subsequently, animals were treated with LEV (800 mg/kg), clozapine (0.1 mg/kg), and DREADD ligand JHU37160 (0.1 mg/kg) and the effect on spontaneous seizures was investigated. Clozapine and JHU37160-mediated chemogenetic treatment both suppressed seizures in DREADD-expressing IHKA mice. Clozapine treatment suppressed seizures up to 34 h after treatment, and JHU37160 effects lasted for 26 h after injection. Moreover, both compounds reduced the length of seizures that did occur after treatment up to 28 h and 18 h after clozapine and JHU37160, respectively. No seizure-suppressing effects were found in control animals using these ligands. Chemogenetic seizure treatment suppressed seizures during the first 30 min after injection, and seizures remained suppressed during 8 h following treatment. Chemogenetics thus outperformed effects of levetiracetam (p < 0.001), which suppressed seizure frequency with a maximum of 55 +/- 9% for up to 1.5 h (p < 0.05). Only chemogenetic and not levetiracetam treatment affected the length of seizures after treatment (p < 0.001). These results show that the chemogenetic therapeutic strategy with either clozapine or JHU37160 effectively suppresses spontaneous seizures in the IHKA mouse model, confirming JHU37160 as an effective DREADD ligand. Moreover, chemogenetic therapy outperforms the effects of levetiracetam, indicating its potential to suppress drug-resistant seizures.}},
  author       = {{Desloovere, Jana and Boon, Paul and Larsen, Lars Emil and Goossens, Marie-Gabrielle and Delbeke, Jean and Carrette, Evelien and Wadman, Wytse and Vonck, Kristl and Raedt, Robrecht}},
  issn         = {{1933-7213}},
  journal      = {{NEUROTHERAPEUTICS}},
  keywords     = {{DREADD,hM4Di,Temporal lobe epilepsy,Anti-epileptic drugs,JHU37160,Clozapine,ANTIEPILEPTIC DRUG EFFICACY,TEMPORAL-LOBE EPILEPSY,KAINATE MODEL,DREADDS,MICE,CIRCUITS,TOOLS}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{342--351}},
  title        = {{Chemogenetic seizure control with clozapine and the novel ligand JHU37160 outperforms the effects of Levetiracetam in the intrahippocampal kainic acid mouse model}},
  url          = {{http://doi.org/10.1007/s13311-021-01160-0}},
  volume       = {{19}},
  year         = {{2022}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: